As TZDs and SGLT2 inhibitors have been reported to improve hepatic steatosis, sensitivity analyses excluding the participant taking a TZD at baseline and excluding the six participants taking SGLT2 inhibitors at baseline are included in Table S1 and Table S2, respectively (Additional file 1). The gene discussed is SLC5A2; the disease is fatty liver disease.